Lexicon Pharmaceuticals Welcomes Tom Garner as Senior Vice President and Chief Commercial Officer

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing innovative medicines, has announced the appointment of Tom Garner as their new senior vice president and chief commercial officer. With over 25 years of experience in the pharmaceutical industry, Garner brings a wealth of knowledge and expertise to his new role.

Garner began his career in the United Kingdom, holding various senior positions at Boehringer Ingelheim and Eli Lilly before joining Bristol Myers Squibb (BMS) in 2002. During his time at BMS, Garner held key roles across different brands and therapeutic areas, including the senior vice president and head of the U.S. Cardiovascular and Established Brands business unit. In this position, he oversaw several successful brands, including ELIQUIS® and CAMZYOS®, and played a crucial role in leading global launches for lung and head and neck cancer programs.

As Lexicon’s chief commercial officer, Garner will play a critical role in driving the launch strategy for INPEFA® (sotagliflozin), a promising treatment for heart failure. His extensive experience in the cardiovascular space and leading successful launches positions him well to contribute to the company’s mission of transforming patients’ lives.

Lonnel Coats, Lexicon’s CEO, expressed excitement about Garner joining the team, emphasizing his breadth and depth of commercial and general management experience. Coats believes that Garner’s expertise will be instrumental in executing the launch strategy for INPEFA and delivering on the brand’s potential to make a difference for patients.

Garner himself expressed enthusiasm about joining Lexicon and leading the commercial organization. He highlighted his vision for the brand and the commercial potential of INPEFA, as well as the opportunity to bring LX9211 to market for diabetic peripheral neuropathic pain. Garner’s passion for making a positive impact aligns with Lexicon’s mission, and he is eager to contribute to the company’s success.

Lexicon Pharmaceuticals is dedicated to pioneering medicines that transform patients’ lives. Through their Genome5000™ program, the company has identified over 100 protein targets with significant therapeutic potential. With a pipeline of promising drug candidates in various indications, including heart failure, neuropathic pain, diabetes, and metabolism, Lexicon continues to advance innovative medicines.

For more information about Lexicon Pharmaceuticals, please visit www.lexpharma.com.